Immunotherapy is a type of treatment that uses the body's own immune system to fight diseases, including cancer. One of the key players in immunotherapy is antibodies.
Antibodies, also known as immunoglobulins, are proteins produced by B-cells that play a critical role in the immune system. They are responsible for identifying and neutralizing foreign substances, such as bacteria and viruses, by binding to them and marking them for destruction by other immune cells.
In recent years, researchers have discovered that antibodies can also be used to target cancer cells. Antibody-based immunotherapies work by using monoclonal antibodies, which are antibodies that are made in the laboratory to target specific proteins on cancer cells. When the monoclonal antibodies bind to the cancer cells, they can trigger an immune response that leads to the destruction of the cancer cells.
At Biointron, we are dedicated to accelerating antibody discovery for the development of new immunotherapies. Our expertise in antibody screening, engineering, and production allows us to provide high-quality antibody services that are critical to the success of immunotherapy research. Learn more about our CHO-K1 stable cell line generation service and how it supports cutting-edge antibody production. For foundational solutions, explore our CHOK1BN cell line commercial license to ensure precision in antibody development.
Through our state-of-the-art manufacturing and automation process, we are able to deliver antibody products that meet international standards in terms of quality, purity, and potency. By working with us, our clients can rest assured that they are receiving the highest quality antibodies for their research and development needs.
As the field of immunotherapy continues to grow and evolve, we are committed to staying at the forefront of antibody discovery and production. With our expertise and dedication to quality, we are proud to play a key role in the development of new immunotherapies that have the potential to transform the way we treat cancer and other diseases.
For an antibody candidate, strong target binding is only part of the path toward……
Explore VHH-based biosensors for high-sensitivity detection using nanobodies in ……
Biointron’s Antibodies After Hours: BIO 2026 Reception was held at The Lion's Sh……
Explore how VHH antibodies stabilize protein conformations for crystallography, ……
You can also contact us on the Scientist and Science Exchange marketplaces.